Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 1997

View Archived Issues

Tsumura describes agents for dermatitis

Chymase inhibitors from Green Cross

Peptide derivatives with antiinflammatory properties described by U.S. researchers

Rockefeller University discloses antibiotic peptides

Merck describes improved chemotherapeutic agents

Il Yang develops antitumor/immunostimulating proteoglycan

Antiallergic/antiinflammatory agents from Senju

Japanese researchers describe triazole antifungals

Nonantiresorptive substituted bisphosphonate disclosed by Gador

Legionella vaccine described by U.S. researchers

Promising new imaging agent for CNS disorders

Potential anticonvulsant described by CoCensys

Follow-up data reported for Amelorad

First launch for SCLC imaging agent

Promising data reported for fomivirsen

Isis updates activities related to ISIS-2302

Isis previews antisense anticancer program

Another Isis antisense compound to enter clinic

Progress in Bone Care's vitamin D pipeline

Zynaxis sells drug delivery technology

Alza signs licensing agreements for transdermal testesterone products

CEAPRO receives patent coverage for potential vaccine adjuvants

Cypress awarded grant for research related to its PROSORBA Column

Unigene Laboratories reveals bioequivalency results for osteoporosis drug

NIH funds development of antiplatelet agents from Cypress/PRP

RPR's docetaxel now approved in 49 countries

Pegasus completes acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...